Abstract: Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.

Abstract: A method of delivering a drug or other compound to the lens of the eye. A conduit through which a drug is introduced penetrates at least the outer lens capsule for drug delivery. When withdrawn, the aperture is self-sealing, thus minimizing trauma and minimizing the risk of cataract formation. The drug remains localized within the lens.

Abstract: Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.

Abstract: A method of introducing a beneficial substance into the body is presented. The method includes the steps of loading biodendrimer with the beneficial substance, and positioning the biodendrimer relative to the body, such that the beneficial substance can be absorbed by the body.

Abstract: The present invention relates to an intraocular lens, including a first lens having a first portion configured to alter light rays passing therethrough in a first manner and form a first image in an eye and a second portion adjacent said first portion. A second lens is coupled to the first lens and a third lens coupled to at least one of the first lens and the second lens. The second lens, third lens and second portion are configured in series such that the lenses from a telescope that alters light rays in a second manner and forms a second image in the eye.

Abstract: A method for the hyperthermia treatment of tissue in a target site applies a heat source to kill cells without protein denaturization. The method introduces an encapsulated dye that is released at a selected temperature in the target site to indicate that a threshold temperature has been reached to hyperthermally treat the tissue. In one embodiment, the composition releases the dye at a temperature of 42° C. to 50° C., and preferably about 45° C. to 49° C. The composition which can be a liposome composition encapsulating the dye can be introduced to the bloodstream of the patient to flow through the target site.

Abstract: Containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.

Abstract: Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.

Abstract: A formulation to treat ocular conditions such as dry eye disease, as well as other conditions, is disclosed. Rapamycin and/or ascomycin is administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. For example, a topical administration may contain between about 50 pg/ml drug to about 50 ?g/ml drug in a formulation which may be applied at bedtime or throughout the day. For injection, a dose of about 50 pg/ml to about 200 ?g/ml may be used. Rapamycin and/or ascomycin may also be administered in milligram quantities as a surgical implant, for example, in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

Abstract: Methods are disclosed to enhance controlled localization and/or release of an agent at an anatomical and/or physiological site where the agent is desirable. In one embodiment, the method localizes vector transfected with a gene(s) that enhances neovascularization (i.e., genes encoding angiogenic agents). In another embodiment, the method localizes genes that inhibit neovascularization (i.e., genes encoding antiangiogenic agents) at sites where new blood vessel growth is undesirable. The vector is provided in a biocompatible substance substantially preventing migration of the vector from the site in need of therapy. The substance may be a matrix, gel, a polymer, liposome, capsule, nanoparticle, microparticle. The substance may form in situ, for example, a fibrin entraining mesh or network form from fibrinogen and thrombin.

Abstract: Formulations and methods useful to treat ocular neovascularization (new blood vessel growth in the cornea, retina, conjunctiva, and/or choroid) are illustrated. According to the invention there is provided a formulation suitable for the treatment of ocular neovascularization that may comprise heparin in a concentration and dose suitable for treating ocular neovascularization, characterized in that said compound is at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye. Use of drugs like steroids in the treatment of such ocular neovascularization ailments can increase intraocular pressure (glaucoma).

Abstract: A system for removing cells from an interior portion of an eye, including a continuous passageway adapted to pass a fluid therethrough. A first cutting device is coupled to an exterior portion of the continuous passageway for dislodging cells from the interior portion of the eye. The first cutting device moves relative to the exterior portion of the continuous passageway due to the passing of the fluid through the continuous passageway.

Abstract: A method for treating or preventing retinal pathology or injury. The method locates and secures a retinal stimulating substance in the eye between the internal limiting membrane and the retina, which is the target site for the substance. The substance may be an implant that provides electrical stimulation to adjacent ganglion and neurofiber cells. Alternatively, the substance may be a pharmaceutical substance to stimulate the retina. In addition to providing direct contact of the substance with its target, the method obviates the need for artificial structures such as tacks or adhesives which may cause retinal bleeding or traction.

Abstract: A method of replacing a natural lens in an eye is presented. The method includes removing the natural lens while leaving the capsular bag substantially intact, removing a portion of the capsular bag along the main optical axis, and placing biodendrimer within the capsular bag. Placing biodendrimer within the capsular bag can include placing a mixture of biodendrimer and at least one other material within the capsular bag. Biodendrimer can be approximately fifty percent of the mixture. The method can also include inserting an artificial bag within the capsular bag, injecting a synthetic material into the artificial bag to form an artificial lens, the synthetic material having loose monomers and a polymerization initiator so that the synthetic material changes its volume when exposed to an energy source, and selectively exposing portions of the artificial lens to an energy source to alter the refractive properties of the artificial lens.

Abstract: A cornea is reshaped by first creating a first cut in the cornea using an ultra-short pulse laser. The first cut is located below the surface of the cornea and does not extend through the epithelium. A second cut is then created using the ultra-short pulse laser. The second cut creates a corneal flap and intersects with the first cut to create a substantially severed portion of the cornea located between the first cut and the second cut. The severed portion of the cornea is located outside of the visual axis of the eye. The corneal flap is lifted away from the severed portion, and the severed portion is removed from the eye. The corneal flap is moved into the space on the cornea previously occupied by the severed portion. The cornea is thereby reshaped, and the reshaped portion of the cornea has an increased refractive power, correcting for hyperopic and presbyopic conditions.

Abstract: A method for reducing irritancy of ascorbic acid administered to a biological surface for anti-angiogenic, anti-oxidant, anti-inflammatory and other effects. It has been discovered that pH neutralized ascorbic acid retains the efficacy of non-pH neutralized ascorbic acid in reducing neovascularization, providing an anti-oxidant effect, etc. but is less irritating and thus enhances patient comfort and compliance. It may be administered into or on the eye, on skin, into a body cavity, etc. either alone or with other agents.

Abstract: The present invention relates to an inlay for correcting refractive error in an eye. The inlay includes a first portion having a first volume that remains substantially constant when exposed to an energy, and a second portion having a second volume that is adapted to change when exposed to the energy. This inlay results in a device that can correct severe ametropic conditions, without ablating any portion of the inlay itself or the cornea.

Abstract: A method of modifying a cornea of an eye to reduce refractive error, the cornea having a surface and a main optical axis, including the steps of aiming and firing a laser at the cornea of the eye. The laser first separates an internal portion of the cornea forming a first internal surface and a second internal surface, the first internal surface facing in a posterior direction of the cornea and the second internal surface facing in an anterior direction of the cornea, with the first and second internal surfaces forming an internal pocket therebetween. An incision is then made from the surface of the cornea to the internal pocket, and an ocular implant is introduced through the incision and into the internal pocket of the cornea.

Abstract: The present disclosure relates to an intraocular lens system. The lens system includes a first lens adapted to be positioned in the anterior chamber of the eye, along an optical axis, a second lens adapted to be positioned in the posterior chamber of the eye along the optical axis and in series with the first lens, and a third lens adapted to be positioned between the first and second lenses along the optical axis. The first, second and third lenses are configured to form a telescopic lens system.

Abstract: An intraocular lens implant has a telescope portion and a transparent peripheral portion coupled to the outside of the telescope portion. The telescope portion has a converging lens and a diverging lens to form a Galilean telescope. The telescope portion provides magnified vision for the central field of vision. The peripheral portion of the implant is adapted to correct for refractive errors and allows for unrestricted peripheral vision.